Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins

Journal of Medicinal Chemistry

Volumn 56, Issue 23, 2013, Pages 9635-9645

  Tanaka, Yuta ^a   Aikawa, Katsuji ^a   Nishida, Goushi ^a   Homma, Misaki ^a   Sogabe, Satoshi ^a   Igaki, Shigeru ^a   Hayano, Yumi ^a   Sameshima, Tomoya ^a   Miyahisa, Ikuo ^a   Kawamoto, Tomohiro ^a   Tawada, Michiko ^a   Imai, Yumi ^a   Inazuka, Masakazu ^a   Cho, Nobuo ^a   Imaeda, Yasuhiro ^a   Ishikawa, Tomoyasu ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 (4 (((4 ((4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YL)AMINO) 3 NITROPHENYL)SULFONYL)CARBAMOYL) 2,6 DIMETHYLPHENYL) 3 (3 (NAPHTHALEN 1 YLOXY)PROPYL)PYRAZOLO[1,5 A]PYRIDINE 2 CARBOXYLIC ACID; 7 (4 (((4 ((4 (DIMETHYLAMINO) 1 (PHENYLTHIO)BUTAN 2 YL)AMINO) 3 NITROPHENYL)SULFONYL)CARBAMOYL)2 METHYLPHENYL) 3 (3 (NAPHTHALEN 1 YLOXY)PROPYL)PYRAZOLO[1,5 A]PYRIDINE 2 CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; BCL XL INHIBITOR; MCL 1 INHIBITOR; NAVITOCLAX; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; PYRAZOLE DERIVATIVE; PYRAZOLO[1,5 A]PYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HYBRIDIZATION; HYDROGEN BOND; IC 50; LIGAND BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 84890465064     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401170c     Document Type: Article

References (40)

1. Fuchs, Y.; Steller, H. Programmed Cell Death in Animal Development and Disease Cell 2011, 147, 742-758
2. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144, 646-674
3. Ziegler, D. S.; Kung, A. L. Therapeutic targeting of apoptosis pathways in cancer Curr. Opin. Oncol. 2008, 20, 97-103
4. Reed, J. C. Apoptosis-based therapies Nature Rev. Drug Discovery 2002, 1, 111-121
5. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points Cell 2004, 116, 205-219
6. Cory, S.; Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch Nature Rev. Cancer 2002, 2, 647-656
7. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 2007, 26, 1324-1337
8. Labi, V.; Erlacher, M.; Kiessling, S.; Villunger, A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy Cell Death Differ. 2006, 13, 1325-1338
9. Youle, R. J.; Strasser, A. The BCL-2 protein family: opposing activities that mediate cell death Nature Rev. Mol. Cell Biol. 2008, 9, 47-59
10. Brown, S. P.; Taygerly, J. P. Small-Molecule Antagonists of Bcl-2 Family Proteins Annu. Rep. Med. Chem. 2012, 47, 253-266
11. Bajwa, N.; Liao, C.; Nikolovska-Coleska, Z. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review Expert Opin. Ther. Pat. 2012, 22, 37-55
12. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681
13. Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis J. Med. Chem. 2006, 49, 656-663
14. Wendt, M. D.; Shen, W.; Kunzer, A.; McClellan, W. J.; Bruncko, M.; Oost, T. K.; Ding, H.; Joseph, M. K.; Zhang, H.; Nimmer, P. M.; Ng, S. C.; Shoemaker, A. R.; Petros, A. M.; Oleksijew, A.; Marsh, K.; Bauch, J.; Oltersdorf, T.; Belli, B. A.; Martineau, D.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo J. Med. Chem. 2006, 49, 1165-1181
15. Park, C. M.; Oie, T.; Petros, A. M.; Zhang, H.; Nimmer, P. M.; Henry, R. F.; Elmore, S. W. Design, synthesis, and computational studies of inhibitors of Bcl-XL J. Am. Chem. Soc. 2006, 128, 16206-16212
16. Bruncko, M.; Oost, T. K.; Belli, B. A.; Ding, H.; Joseph, M. K.; Kunzer, A.; Martineau, D.; McClellan, W. J.; Mitten, M.; Ng, S. C.; Nimmer, P. M.; Oltersdorf, T.; Park, C. M.; Petros, A. M.; Shoemaker, A. R.; Song, X.; Wang, X.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL J. Med. Chem. 2007, 50, 641-662
17. Park, C. M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Marsh, K. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins J. Med. Chem. 2008, 51, 6902-6915
18. Shoemaker, A. R.; Mitten, M. J.; Adickes, J.; Ackler, S.; Refici, M.; Ferguson, D.; Oleksijew, A.; O'Connor, J. M.; Wang, B.; Frost, D. J.; Bauch, J.; Marsh, K.; Tahir, S. K.; Yang, X.; Tse, C.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. W. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models Clin. Cancer Res. 2008, 14, 3268-3277
19. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 2008, 68, 3421-3428
20. Wendt, M. D. Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction. Expert Opin. Drug Discovery 2008, 3, 1123-1143
21. Roberts, A. W.; Seymour, J. F.; Brown, J. R.; Wierda, W. G.; Kipps, T. J.; Khaw, S. L.; Carney, D. A.; He, S., Z.; Huang, D. C.; Xiong, H.; Cui, Y.; Busman, T. A.; McKeegan, E. M.; Krivoshik, A. P.; Enschede, S. H.; Humerickhouse, R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease J. Clin. Oncol. 2012, 5, 488-496
22. Rudin, C. M.; Hann, C. L.; Garon, E. B.; Ribeiro de Oliveira, M.; Bonomi, P. D.; Camidge, D. R.; Chu, Q.; Giaccone, G.; Khaira, D.; Ramalingam, S. S.; Ranson, M. R.; Dive, C.; McKeegan, E. M.; Chyla, B. J.; Dowell, B. L.; Chakravartty, A.; Nolan, C. E.; Rudersdorf, N.; Busman, T. A.; Mabry, M. H.; Krivoshik, A. P.; Humerickhouse, R. A.; Shapiro, G. I.; Gandhi, L. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Clin. Cancer Res. 2012, 18, 3163-3169
23. Elmore, S. W.; Souers, A. J.; Bruncko, M.; Song, X.; Wang, X.; Hasvold, L. A.; Wang, L.; Kunzer, A. R.; Park, C.; Wendt, M. D.; Tao, Z. 7-Substituted indole Mcl-1 inhibitors. WO2008131000A2, 2008.
24. Friberg, A.; Vigil, D.; Zhao, B.; Daniels, R. N.; Burke, J. P.; Garcia-Barrantes, P. M.; Camper, D.; Chauder, B. A.; Lee, T.; Olejniczak, E. T.; Fesik, S. W. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design J. Med. Chem. 2013, 56, 15-30
25. Konopleva, M.; Contractor, R.; Tsao, T.; Samudio, I.; Ruvolo, P. P.; Kitada, S.; Deng, X.; Zhai, D.; Shi, Y. X.; Sneed, T.; Verhaegen, M.; Soengas, M.; Ruvolo, V. R.; McQueen, T.; Schober, W. D.; Watt, J. C.; Jiffar, T.; Ling, X.; Marini, F. C.; Harris, D.; Dietrich, M.; Estrov, Z.; McCubrey, J.; May, W. S.; Reed, J. C.; Andreeff, M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia Cancer Cell 2006, 10, 375-388
26. van Delft, M. F.; Wei, A. H.; Mason, K. D.; Vandenberg, C. J.; Chen, L.; Czabotar, P. E.; Willis, S. N.; Scott, C. L.; Day, C. L.; Cory, S.; Adams, J. M.; Roberts, A. W.; Huang, D. C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 2006, 10, 389-399
27. Chen, S.; Dai, Y.; Harada, H.; Dent, P.; Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation Cancer Res. 2007, 67, 782-791
28. Tahir, S.; Yang, X.; Anderson, M.; Morgan-Lappe, S.; Sarthy, A.; Chen, J.; Warner, R.; Ng, S.; Fesik, S.; Elmore, S.; Rosenberg, S.; Tse, C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737 Cancer Res. 2007, 67, 1176-1183
29. Lam, L.; Lu, X.; Zhang, H.; Lesniewski, R.; Rosenberg, S.; Semizarov, D. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax) Mol. Cancer Ther. 2010, 9, 2943-2950
30. L: implications for selectivity of antagonists of Bcl-2 family Cell Death Differ. 2007, 14, 1711-1713
31. Czabotar, P. E.; Lee, E. F.; Thompson, G. V.; Wardak, A. Z.; Fairlie, W. D.; Colman, P. M. Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis J. Biol. Chem. 2011, 286, 7123-7131
32. Hadjuk, P. J. Fragment-based drug design: How big is too big? J. Med. Chem. 2006, 49, 6972-6976
33. L dimerization by three dimensional domain swapping J. Mol. Biol. 2006, 356, 367-381
34. 3,5]non-7-enes) and intramolecular interception of nitrile ylides by neighbouring π-bonds or nucleophiles J. Chem. Soc., Perkin Trans. 1 1986, 1119-1122
35. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In Macromolecular Crystallography, Part A; Carter, C. W., Jr.; Sweet, R. M., Eds.; Academic Press: San Diego, CA, 1997; Vol. 276, pp 307-326.
36. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement J. Appl. Crystallogr. 1997, 30, 1022-1025
37. Bailey, S. The CCP4 suite-programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763
38. Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 355-367
39. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 486-501
40. Chen, V. B.; Arendall, W. B, III; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom structure validation for macromolecular crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 12-21